TAL Education Group header image

TAL Education Group

TAL

Equity

ISIN null / Valor 11869921

New York Stock Exchange, Inc (2025-11-21)
USD 10.94+2.24%

TAL Education Group
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

TAL Education Group is a leading smart learning solutions provider in China, offering comprehensive learning services to students of all ages through various class formats. The company focuses on providing high-quality teaching, content, and technology applications to promote top learning opportunities for students. TAL Education Group's services include enrichment learning programs and academic subjects, both in and out of China. The company's ADSs trade on the New York Stock Exchange under the symbol "TAL".

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (21.11.2025):

TAL Education Group reported unaudited results for the second quarter of fiscal year 2026 (ended August 31, 2025). Net revenues rose 39.1% year‑over‑year to US$861.4 million, operating and net income more than doubled versus the prior year period, and total cash, cash equivalents and short‑term investments were US$3,248.8 million. The company cited growth across enrichment learning programs and learning devices while continuing investments in user experience, technology and educational models.

Revenue

Net revenues for Q2 FY2026 were US$861.4 million, up 39.1% year‑over‑year. For the first six months, net revenues were US$1,436.4 million, up 39.0% year‑over‑year.

Profitability

Income from operations in Q2 was US$96.1 million (up 101.8% y/y). Non‑GAAP income from operations was US$107.8 million. Net income attributable to TAL was US$124.1 million (up 116.1%); non‑GAAP net income was US$135.8 million.

Earnings per ADS

Basic net income per ADS was US$0.22 and diluted was US$0.21 for Q2 FY2026. Non‑GAAP basic and diluted net income per ADS were both US$0.24. (Three ADSs represent one Class A common share.)

Margins and operating costs

Gross profit was US$491.0 million and gross margin was 57.0% (vs. 56.3% a year earlier). Total operating costs and expenses were US$766.7 million (up 34.0%); selling and marketing expenses rose 46.9% to US$267.3 million.

Cash, liquidity and cash flow

As of August 31, 2025, cash and cash equivalents were US$1,542.2 million and short‑term investments were US$1,706.6 million (total US$3,248.8 million), down from US$3,618.4 million as of February 28, 2025. Net cash used in operating activities in Q2 was US$58.1 million.

Deferred revenue

Deferred revenue increased to US$822.7 million as of August 31, 2025, from US$671.2 million as of February 28, 2025.

Other notable items

Other income was US$67.1 million in Q2 (vs. US$20.5 million prior year). Income tax expense was US$51.1 million. Impairment loss on long‑term investments was US$1.4 million. Share‑based compensation allocated to operating costs decreased 30.5% to US$11.8 million in the quarter.

Management commentary

Management highlighted progress in core businesses (enrichment programs and learning devices), continued investments in UX, technology and educational model innovation, and a strategic focus on sustainable growth and expanding access to high‑quality educational content (comments from Alex Peng, President & CFO).

Summarized from source with an LLMView Source

Key figures

11.5%1Y
117%3Y
-85.3%5Y

Performance

56.4%1Y
64.8%3Y
98.0%5Y

Volatility

Market cap

2529 M

Market cap (USD)

Daily traded volume (Shares)

4,428,134

Daily traded volume (Shares)

1 day high/low

9.735 / 9.5

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Straumann Holding Ltd
Straumann Holding Ltd Straumann Holding Ltd Valor: 117544866
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.30%CHF 96.58
National Healthcare Corp
National Healthcare Corp National Healthcare Corp Valor: 836282
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.42%USD 130.44
Maternus-Kliniken AG
Maternus-Kliniken AG Maternus-Kliniken AG Valor: 335800
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.94%EUR 1.05
Dyne Therapeutics Inc
Dyne Therapeutics Inc Dyne Therapeutics Inc Valor: 56806425
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.27%USD 21.18
Baxter International Inc
Baxter International Inc Baxter International Inc Valor: 911702
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.11%USD 18.31
COSMO Pharmaceuticals N.V.
COSMO Pharmaceuticals N.V. COSMO Pharmaceuticals N.V. Valor: 32590356
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.45%CHF 67.10
Astrana Health Inc
Astrana Health Inc Astrana Health Inc Valor: 28041888
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
10.62%USD 22.50
H. Lundbeck A/S
H. Lundbeck A/S H. Lundbeck A/S Valor: 119252587
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.09%DKK 44.18
Embla Medical hf
Embla Medical hf Embla Medical hf Valor: 1060135
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.20%DKK 33.80
MannKind Corp
MannKind Corp MannKind Corp Valor: 35935511
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.21%USD 5.03